 DNA encoding stationary phase, stress response sigma factor from Mycobacterium tuberculosis |
| OF THE INVENTION It is a discovery of the present invention that entry of M. tuberculosis into a ... |
|
| Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use |
| The present invention provides, among other things, a method of removing virus from a sample. The ... |
|
| .alpha.-.beta. C4BP-type recombinant heteromultimeric proteins |
| The object of the present invention is therefore to develop recombinant soluble heteromultimeric ... |
|
| Semi-refined carrageenan |
| The present invention provides methods for preparing a carrageenan product comprising the steps of ... |
|
| Method for improving genetic stability of foreign insert nucleotide sequence in recombinant poliovirus |
| To be free from shortcomings of the poliovirus vector systems, in particular, genetic instability ... |
|
| Dedifferentiated, programmable stem cells of monocytic origin, and their production and use |
| The invention relates to adult dedifferentiated programmable stem cells derived from human ... |
|
| Peptides which enhance transport across tissues and methods of identifying and using the same |
| The invention provides a method of identifying a peptide which permits or facilitates the transport ... |
|
| Synthetic peptides and kits for diagnosis of anti-phospholipid syndrome |
| The invention claimed is: 1. A synthetic peptide selected from the group consisting: (i) a peptide ... |
|
| Synthetic peptide inhibitors of HIV transmission |
| OF THE INVENTION 5.1 DP-178 AND DP-178-LIKE PEPTIDES 5.2 ASSAYS FOR ANTIVIRAL ACTIVITY 5.3 USES OF ... |
|
| Compounds which inhibit HIV replication |
| A first aspect of the present invention is a peptide selected from the group consisting of: (a) the ... |
|
|
Immune suppressive product
| Details |
Inventors: Beck, Lee R.; Stolle, Ralph J.;
Assignee: Stolle Research & Development Corporation (Cincinnati, OH)
Primary Examiner: Scheiner; Laurie
Assistant Examiner:
Attorney, Agent or Firm: Sterne, Kessler, Goldstein & Fox P.L.L.C.
An immune suppressive product prepared by injecting an allergen or a mixture of allergens into the body of milk-producing species. Said product being the milk or a polypeptide subfraction of milk obtained from the allergen treated host. The immune suppressive product(s) is milk and or the polypeptide fractions contained therein, which is ostensively free of the intact allergen or allergens used for the treatment of the host. The immune suppressive factor(s) being a subfraction of the allergen used for the treatment. A method of preparing immune suppressive polypeptides from intact allergens, which involves injection of the specific intact allergens into a milk-producing species, collecting the immune suppressive polypeptide fractions of the intact allergens from the milk of the treated host. The immune suppressive milk containing said polypeptide fractions, and/or the polypeptide fractions obtained from said milk, are nonreactive in animals and humans as allergens. Said factor(s), however, are highly effective in preventing or alleviating allergic reactions. |
|
DETAILED DESCRIPTION What is claimed is: 1.
An oral vaccine, wherein said vaccine comprises a composition wherein said composition comprises a non-antibody fraction of milk and wherein said non-antibody fraction of milk ameliorates, in a subject with an allergy to an allergen, the symptoms of said allergy of said subject to said allergen when said fraction is ingested by said subject and wherein said fraction is produced by the process comprising: (a) administering said allergen to a milk-producing animal; (b) collecting the milk from said animal of part (a); (c) filtering the milk of part (b) through a filter which excludes molecules of greater than 100,000 daltons; and (d) collecting the effluent from the filtration of part (c) wherein said effluent contains said fraction.
Description:
FIELD OF THE INVENTION This invention is directed to the discovery of polypeptide fractions in milk which contain peptides derived from allergens administered to a milk-producing animal.
These fractions are useful in suppressing allergic responses in humans and animals.
BACKGROUND OF THE INVENTION The allergic reaction in man and animals has been extensively studied and the basic immune mechanisms involved are well known.
The generic name for molecules that cause an allergic reaction is allergen.
There are numerous species of allergens.
Common examples include plant pollens, bee venom, house dust, animal dander, and a wide array of food proteins.
Many allergens are protein or polypeptide in nature, as proteins and polypeptides are generally more antigenic than carbohydrates or fats.
The allergic reaction occurs when tissue-sensitizing immunoglobulin of the IgE type reacts with foreign allergen.
The IgE antibody is bound to mast cells and/or basophils, and these specialized cells release chemical mediators of the allergic reaction when stimulated to do so by divalent antigens bridging the antibody molecules.
Histamine, platelet activating factor, arachidonic acid metabolites, and serotonin are among the best known mediators of allergic reactions in man
|
|
Drugs 
